Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • BillPay Log In Required
    • BillPay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Tax Forms & Information
    • Retirement DistributionsLog In Required
    • Fidelity Rewards+Log In Required
    • New Account ChecklistLog In Required
  • Planning & Advice
    • What We Offer
    • My Goals
    • Financial Basics
    • Building Savings
    • Digital Investing & Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
  • News & Research
    • News
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Trading
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sector Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Account
    • Annuities
    • Life Insurance & Long Term Care
    • Charitable Giving
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


Find Symbol. Opens in new window.
  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BY GlobeNewswire
— 4:30 PM ET 09/04/2020

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (ASMB) , a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of stock options to five new employees to purchase an aggregate of 86,000 shares of the Company’s common stock with an exercise price of $20.14 per share, the closing price of Assembly’s common stock on September 1, 2020. The stock options were granted as material inducements to the new employees to accept the Company’s offers of employment.

The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in approximately equal monthly installments. The stock options are, in all cases, subject to the new employees’ continued service with Assembly through the applicable vesting dates and to acceleration upon the occurrence of certain events as set forth in the award agreements evidencing the stock options. None of the new employees are executive officers.

The stock options were granted outside of Assembly’s stockholder-approved equity incentive plans pursuant to Assembly’s 2020 Inducement Award Plan. The stock option awards were approved by the Compensation Committee of Assembly’s Board of Directors, which is comprised solely of independent directors, as a material inducement to entering into employment with Assembly in accordance with Nasdaq Listing Rule 5635(c)(4), which requires this public announcement.

About Assembly Biosciences
Assembly Biosciences (ASMB), Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Contacts
Assembly Biosciences, Inc. (ASMB)
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
lglaser@assemblybio.com


Image: AssemblyBio_logo_RGB.png

Source: Assembly Biosciences, Inc. (ASMB)

More ASMB News

  • Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020
    GlobeNewswire - 6:00 AM ET 08/28/2020
  • Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
    GlobeNewswire - 8:00 AM ET 08/27/2020
  • Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire - 4:30 PM ET 08/07/2020
Fidelity Investments. Copyright 1998–2021 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close